您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 创始合伙人、创始人
所属公司: 安龙基金、安龙生物
个人简介:
赵春林 博士,安龙基金创始合伙人,安龙生物创始人,为清华大学生物系首届毕业生,获得美国匹兹堡医学院分子生物学博士和芝加哥大学工商管理硕士,曾任美国辉瑞制药资深经理,国科嘉和及康桥资本董事总经理,拥有三十多年生命科学及医疗健康领域的创业和投资经验,投资过信达生物,贝瑞合康,天镜生物,歌礼药业,莱凯医药,创响生物及国科恒泰等杰出企业。赵春林博士曾任清华大学生命科学院,医学院及药学院首届校友会主席,为百华协会资深会员。 安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金,投资领域横跨生命科学,医药研发,医疗器械,医疗服务及相关领域。 安龙生物是国内核酸药物领先企业,专注基因治疗,RNA,基因编辑等核酸药物的新药研发。专业之外,赵春林博士喜欢足球,滑雪,曾做过DJ,拥有三个漂亮可爱的女儿。Chunlin Zhao, Ph.DFounder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences,School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 联合创始人/CTO
所属公司: 北京启辰生生物科技有限公司
个人简介:
曾任中国科学院北京基因组研究所研究生导师、2015年度国家十三五传染病重大专项首席科学家;参加十一五重大药物研发专项、承担十二五、十三五 “重大新药”创制项目;目前主持多项科技部和地方科委课题。国家和浙江、福建等省自然科学基金委评审专家;多个杂志编委;发表SCI论文 50余篇。Dr.Shi-you Li, Principle Investigator at Chinese Academy of Sciences Beijing Institute of Genomics prior to the founding of TRICISION BIO Ltd., Chief Scientist of the 13th Five-Year Plan National Major Project for Infectious Diseases in 2015, participated in the 11th Five-Year Plan Major Project for drug development and the 12th and 13th Five-Year Plan “Major New Drug” Development and Manufactor Project. Currently, Dr.Li presides over a number of projects of the Ministry of Science and Technology and local science and technology commissions, and is the peer review expert of the National and Zhejiang, Fujian and other provincial natural science foundations. Dr.Li has more than 50 scientific publication, and is on the editorial board for multiple journals.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 董事长兼CEO
所属公司: 苏州克睿基因生物科技有限公司
个人简介:
南京大学本科,清华大学博士,耶鲁大学医学院博士后、副研究员,历任麦肯锡咨询顾问,上市公司生物药发现&研发副总,现任苏州克睿基因生物科技有限公司董事长。克睿基因2016年在苏州成立,是一家专注于病毒递送系统及基因编辑系统应用开发的创新基因细胞治疗公司,致力于开发肿瘤和遗传疾病。公司成立以来完成近1亿美元融资,并率先完成国内首个病毒载体领域与全球Top20制药公司的授权合作,建成了11000㎡的高规格基因编辑和基因治疗研发生产中心。
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 创始人
所属公司: 嘉晨西海生物技术有限公司
个人简介:
嘉晨西海生物技术有限公司创始人王子豪博士毕业于美国约翰霍普金斯大学,毕业后曾就职于多个国际大型制药企业长达 11 年之久,在职期间直接参与过四价流感、艾滋病、狂犬病、呼吸道合胞病毒、人巨细胞病毒等疫苗的 CMC 开发。王子豪博士作为最早参与自复制 mRNA 工艺设计优化和产业化开发的人员之一,专注于 mRNA 技术平台的工艺开发8年,并且直接参与了 mRNA 技术平台在多个病毒传染病领域的有效性及安全性验证和临床开发等。Dr. Zihao Wang is the Chief Executive Officer at Immorna and Co-founder of the Immorna family of companies. Dr. Wang is a seasoned entrepreneur and established biopharmaceutical veteran. He has over 14 years of biotech R&D and leadership experience. He is one of the pioneers in self-replicating mRNA (srRNA) CMC development and is the mastermind behind the development of the mRNA platform technologies at Immorna, which include an improved next generation srRNA, conventional mRNA, and circular RNA. Dr. Wang pioneers the application of srRNA-LNP against oncology indications.Prior to founding the Immorna family of companies, Dr. Wang held various R&D roles at GSK Vaccines, Novartis Vaccines and Diagnostics, Grifols SA, etc. During his tenure at Novartis and GSK, he spent more than 7 years working directly on srRNA CMC development and the application of srRNA technology against various viral infectious diseases.Dr. Wang is the lead author on more than 20 publications with more than 2000 citations. He is also the inventor on multiple patents related to mRNA design, RNA delivery, and their applications in various disease areas. Dr. Wang received his B.S. in Biochemistry from Fudan University in Shanghai, and his Ph.D. in Biological Chemistry from The Johns Hopkins University.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务